PE20090607A1 - PHARMACEUTICAL FORMULATION OF LIPOSOMAL DISPERSION IN DRY POWDER - Google Patents
PHARMACEUTICAL FORMULATION OF LIPOSOMAL DISPERSION IN DRY POWDERInfo
- Publication number
- PE20090607A1 PE20090607A1 PE2008001429A PE2008001429A PE20090607A1 PE 20090607 A1 PE20090607 A1 PE 20090607A1 PE 2008001429 A PE2008001429 A PE 2008001429A PE 2008001429 A PE2008001429 A PE 2008001429A PE 20090607 A1 PE20090607 A1 PE 20090607A1
- Authority
- PE
- Peru
- Prior art keywords
- inhibitor
- caspasa
- dry powder
- pharmaceutical formulation
- antabidor4
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000006185 dispersion Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 7
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 abstract 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 abstract 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 abstract 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 abstract 1
- 229920001202 Inulin Polymers 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 abstract 1
- 229930195725 Mannitol Natural products 0.000 abstract 1
- UQOFGTXDASPNLL-XHNCKOQMSA-N Muscarine Chemical compound C[C@@H]1O[C@H](C[N+](C)(C)C)C[C@H]1O UQOFGTXDASPNLL-XHNCKOQMSA-N 0.000 abstract 1
- -1 SACROSE Chemical compound 0.000 abstract 1
- 239000008186 active pharmaceutical agent Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 229940124748 beta 2 agonist Drugs 0.000 abstract 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 abstract 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 abstract 1
- 235000012000 cholesterol Nutrition 0.000 abstract 1
- 239000008121 dextrose Substances 0.000 abstract 1
- 229940088679 drug related substance Drugs 0.000 abstract 1
- 238000005538 encapsulation Methods 0.000 abstract 1
- 239000003623 enhancer Substances 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 239000003862 glucocorticoid Substances 0.000 abstract 1
- 229940029339 inulin Drugs 0.000 abstract 1
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000000594 mannitol Substances 0.000 abstract 1
- 235000010355 mannitol Nutrition 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940083466 soybean lecithin Drugs 0.000 abstract 1
- 239000000126 substance Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Otolaryngology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE: A) UNA O MAS SUSTANCIAS MEDICAMENTOSAS SELECCIONADAS DE AGONISTA DEL ADRENORECEPTOR -BETA2, ANTAGONISTA MUSCARINICO, GLUCOCORTICOSTEROIDE, INHIBIDOR DE CASPASA, ANTAGONISTA LTB4, INHIBIDOR DE FOSFODIESTERASA, ENTRE OTROS; B) UN LIPIDO SELECCIONADO DE DIMARSETOIL, FOSAFATIDILCOLINA, LECITINA DE SOJA, DIPALMITOIL FOSFATIDILCOLINA, ENTRE OTROS; C) UN COLIPIDO SELECCIONADO DE FOSFATIDILCOLINA PEGILADA, COLESTEROL; D) MEJORADOR DE FLUJO TAL COMO MALTOSA, MANITOL, INULINA, SACAROSA, LACTOSA, DEXTROSA, ENTRE OTROS. DICHA FORMULACION DITRIBUYE SUSTANCIAS MEDICAMENTOSAS MEDIANTE LA ENCAPSULACION LIPOSOMAL AUMENTANDO LA EFICIENCIA DE ATRAPAMIENTO DEL INGREDIENTE ACTIVO FARMACEUTICOIT REFERS TO A PHARMACEUTICAL COMPOSITION THAT INCLUDES: A) ONE OR MORE MEDICINAL SUBSTANCES SELECTED FROM ADRENORECEPTOR -BETA2 AGONIST, MUSCARINE ANTAGONIST, GLUCOCORTICOSTEROID, CASPASA INHIBITOR, OTHEBIDOR4ISTEROSH INHIBITOR, INHIBITOR OF CASPASA, ANTABIDOR4 INHIBITOR OF INHIBITOR, INHIBITOR OF CASPASA, ANTABIDOR4 INHIBITOR OF THE B) A LIPID SELECTED FROM DIMARSETOIL, PHOSPHATIDYLCHOLINE, SOYBEAN LECITHIN, DIPALMITOIL PHOSPHATIDYLCOLINE, AMONG OTHERS; C) A COLLIPID SELECTED FROM PEGILATED PHOSPHATIDYLCHOLINE, CHOLESTEROL; D) FLOW ENHANCER SUCH AS MALTOSE, MANNITOL, INULIN, SACROSE, LACTOSE, DEXTROSE, AMONG OTHERS. SUCH FORMULATION DISTRIBUTES DRUG SUBSTANCES THROUGH LIPOSOMAL ENCAPSULATION, INCREASING THE TRAPPING EFFICIENCY OF THE ACTIVE PHARMACEUTICAL INGREDIENT
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07114981 | 2007-08-24 | ||
| EP07123163 | 2007-12-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20090607A1 true PE20090607A1 (en) | 2009-06-11 |
Family
ID=40149638
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2008001429A PE20090607A1 (en) | 2007-08-24 | 2008-08-22 | PHARMACEUTICAL FORMULATION OF LIPOSOMAL DISPERSION IN DRY POWDER |
Country Status (5)
| Country | Link |
|---|---|
| AR (1) | AR067997A1 (en) |
| CL (1) | CL2008002479A1 (en) |
| PE (1) | PE20090607A1 (en) |
| TW (1) | TW200916126A (en) |
| WO (1) | WO2009027337A1 (en) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2007264418B2 (en) | 2006-06-30 | 2012-05-03 | Iceutica Pty Ltd | Methods for the preparation of biologically active compounds in nanoparticulate form |
| KR20120101285A (en) | 2009-04-24 | 2012-09-13 | 아이슈티카 피티와이 리미티드 | A novel formulation of indomethacin |
| WO2013009928A1 (en) | 2011-07-11 | 2013-01-17 | Organic Medical Research | Cannabinoid formulations |
| WO2013164380A1 (en) * | 2012-05-03 | 2013-11-07 | Janssen R&D Ireland | Polyinosinic-polycytidylic acid (poly (i:c)) formulations for the treatment of upper respiratory tract infections |
| WO2018160295A1 (en) * | 2017-01-25 | 2018-09-07 | Yiannios James John | Dietary supplement compositions with enhanced delivery matrix, gummies, chocolates, atomizers and powders containing same, and methods of making same |
| US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
| MX2020007559A (en) | 2018-02-01 | 2020-09-03 | Corvus Pharmaceuticals Inc | Pharmaceutical formulations. |
| EP3520782A3 (en) * | 2018-02-01 | 2019-11-13 | Corvus Pharmaceuticals, Inc. | Pharmaceutical formulations containing adenosine a2a receptor antagonists |
| MX2021005508A (en) * | 2018-11-13 | 2021-09-08 | Civitas Therapeutics Inc | Respirable polynucleotide powder formulations for inhalation. |
| US10729687B1 (en) * | 2019-07-09 | 2020-08-04 | Orexo Ab | Pharmaceutical composition for nasal delivery |
| CN114206906B (en) * | 2019-07-10 | 2024-02-20 | 香港大学 | PEGylated synthetic KL4 peptides, compositions and methods thereof |
| CN114209651A (en) * | 2021-11-18 | 2022-03-22 | 上海欣峰制药有限公司 | Pharmaceutical preparation of cefotaxime sodium compound and preparation method thereof |
| CN114053226A (en) * | 2021-11-18 | 2022-02-18 | 上海欣峰制药有限公司 | Pharmaceutical preparation of cefminox sodium compound and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0843555B1 (en) * | 1995-08-01 | 2003-08-27 | Isis Pharmaceuticals, Inc. | Liposomal oligonucleotide compositions |
| CA2522637C (en) * | 2003-04-17 | 2014-01-21 | Alnylam Pharmaceuticals, Inc. | Modified irna agents |
| JPWO2005011632A1 (en) * | 2003-08-01 | 2006-09-14 | 独立行政法人産業技術総合研究所 | Target-directed and intestinal absorption-controllable liposomes having sugar chains and cancer therapeutics and diagnostics containing the same |
| US8017804B2 (en) * | 2004-05-05 | 2011-09-13 | Silence Therapeutics Ag | Lipids, lipid complexes and use thereof |
| GB0418172D0 (en) * | 2004-08-13 | 2004-09-15 | Ic Vec Ltd | Vector |
| WO2006080118A1 (en) * | 2005-01-28 | 2006-08-03 | Kyowa Hakko Kogyo Co., Ltd. | Composition for inhibiting expression of target gene |
| US20070172430A1 (en) * | 2006-01-20 | 2007-07-26 | Nastech Pharmaceutical Company Inc. | Dry powder compositions for rna influenza therapeutics |
| EP2007356B1 (en) * | 2006-04-20 | 2015-08-12 | Silence Therapeutics GmbH | Lipoplex formulations for specific delivery to vascular endothelium |
| GB0608838D0 (en) * | 2006-05-04 | 2006-06-14 | Novartis Ag | Organic compounds |
-
2008
- 2008-08-21 AR ARP080103643A patent/AR067997A1/en unknown
- 2008-08-22 TW TW097132233A patent/TW200916126A/en unknown
- 2008-08-22 CL CL2008002479A patent/CL2008002479A1/en unknown
- 2008-08-22 WO PCT/EP2008/061018 patent/WO2009027337A1/en not_active Ceased
- 2008-08-22 PE PE2008001429A patent/PE20090607A1/en not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AR067997A1 (en) | 2009-10-28 |
| CL2008002479A1 (en) | 2009-05-08 |
| TW200916126A (en) | 2009-04-16 |
| WO2009027337A1 (en) | 2009-03-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20090607A1 (en) | PHARMACEUTICAL FORMULATION OF LIPOSOMAL DISPERSION IN DRY POWDER | |
| ECSP10010224A (en) | LUTEINIZING HORMONE LIQUID FORMULATIONS (LH). | |
| WO2009088414A3 (en) | Oral pharmaceutical dosage forms | |
| MX2015009772A (en) | Spiro-lactam nmda receptor modulators and uses thereof. | |
| CL2008000442A1 (en) | PHARMACEUTICAL COMPOSITION THAT INCLUDES A CHITOSAN, A COSMETIC OR PHARMACEUTICAL ACTIVE INGREDIENT, AND A VOLATILE SOLVENT; AND ITS USE TO TREAT PSORIASIS, MICOSIS BETWEEN OTHER DISEASES. | |
| CU20080052A7 (en) | SOLID PHARMACEUTICAL PRESENTATION FORMS OF ORAL ADMINISTRATION WITH QUICK RELEASE OF ACTIVE PRINCIPLE | |
| AR051969A1 (en) | METHODS AND COMPOSITIONS THAT USE IMMUNOMODULATING COMPOUNDS FOR THE TREATMENT AND MANAGEMENT OF INJURIES OF THE CENTRAL NERVOUS SYSTEM | |
| CR20110110A (en) | PHARMACEUTICAL COMPOSITION | |
| SV2009003231A (en) | USE OF ESTRADIOL VALERATE OR 17B-ESTRADIOL IN COMBINATION WITH DIENOGEST IN AN ORAL THERAPY TO MAINTAIN AND / OR IMPLEMENT FEMALE FREE | |
| NO20081038L (en) | Pharmaceutical formulations / compositions of guanfacine suitable for daily single dosage form administration | |
| AR070026A1 (en) | SET OF ELEMENTS FOR THE DOSAGE OF 1-AMINO-ALQUILCICLOHEXANOS, SUCH AS NERAMEXAN, AND TREATMENT OF DIFFERENT DISEASES INCLUDING TINNITUS | |
| IL195269A0 (en) | Pharmaceutical formulations for the sustained release of active ingredient(s), as well as their applications, especially therapeutic | |
| WO2010021607A3 (en) | Pharmaceutical formulation | |
| PH12014502331B1 (en) | Orally available pharmaceutical formulation suitable for improved management of movement disorders | |
| NI201100154A (en) | METHODS OF USE AND COMPOSITIONS INCLUDING PDE4 MODULATORS FOR THE TREATMENT, PREVENTION AND MANAGEMENT OF TUBERCULOSIS | |
| UY29561A1 (en) | DERIVATIVES OF QUINAZOLINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM, PREPARATION PROCEDURES AND APPLICATIONS | |
| WO2008128191A3 (en) | Oral cephalotaxine dosage forms | |
| EP3453702A3 (en) | Parasiticidal compositions comprising benzimidazole derivatives, methods and uses thereof | |
| WO2010029093A3 (en) | Compositions for percutaneous administration | |
| MX391191B (en) | EXTENDED-RELEASE COMPOSITIONS OF ONAPRISTONE AND METHODS. | |
| ES2325291A1 (en) | "USE OF A SILYBUM MARIANUM EXTRACT" | |
| AR075866A1 (en) | A DOSE OF AVE5026 FOR THE TREATMENT OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH SEVERE RENAL DETERIORATION. USE. PHARMACEUTICAL COMPOSITION | |
| TR201803451T4 (en) | OLMESARTAN FORMULATIONS. | |
| AR091234A1 (en) | PHARMACEUTICAL FORMULATIONS BASED ON GENOTYPES OR PHENOTYPES, PROCEDURE TO PREPARE THEM | |
| AR086252A1 (en) | TOPICAL FORMULATION THAT INCLUDES BECLOMETASONE DIPROPIONATE AS ACTIVE INGREDIENT |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FX | Voluntary withdrawal |